Last reviewed · How we verify
NCT00003646
Phase II Study of Allovectin-7 as an Immunotherapeutic Agent in Patients With Stages III and IV Melanoma
Phase 2 trial testing allovectin-7 in Stage IV Melanoma in 78 participants. Completed in 1 May 2002.
1 March 2002
Quick facts
| Lead sponsor | Vical |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 78 |
| Start date | 1 August 1998 |
| Primary completion | 1 March 2002 |
| Estimated completion | 1 May 2002 |
| Sites | 3 locations across United States |
Drugs / interventions tested
- allovectin-7 — full drug profile →
Conditions studied
- Stage IV Melanoma — all drugs for Stage IV Melanoma →
- Stage III Melanoma — all drugs for Stage III Melanoma →
- Recurrent Melanoma — all drugs for Recurrent Melanoma →
Sponsor
Vical — full company profile →
Who can join
18 and older, any sex, with Stage IV Melanoma or Stage III Melanoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
RATIONALE: Injecting allovectin-7 into a person's melanoma cells may make the body build an immune response that will kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of gene therapy in treating patients who have stage III or stage IV melanoma that has not responded to previous treatment.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Recent advances in the bench-to-bedside translation of cancer nanomedicines.
Liu Y, Zhang Y, Li H, Hu TY. · · 2025 · cited 27× · PMID 40041906 · DOI 10.1016/j.apsb.2024.12.007
Verify or expand the search:
- PubMed search for NCT00003646
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Stage IV Melanoma
Currently open trials in the same condition.
- NCT06416085 — Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer · Phase 2 · active not recruiting
- NCT05176470 — Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients · Phase 1 · active not recruiting
- NCT07376317 — Optimization of Immunotherapy Treatment for Advanced Melanoma in the Context of the Public Brazilian Health System (OTIM · Phase 2 · active not recruiting
- NCT04356729 — A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma · Phase 2 · active not recruiting
Other Vical trials
Trials by the same sponsor.
- NCT03327727 — VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults · Phase 2 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00003646 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Vical
- Last refreshed: 5 July 2011
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00003646.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing